Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from TDF/other oral antivirals to TAF in virologically suppressed chronic hepatitis B with renal and/or hepatic impairment
2016-004625-16Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tenofovir alafenamide in Chronic Hepatitis B (CHB), sponsored by Gilead Sciences. Started Aug 2017; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2016-004625-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004625-16.